- Home
- SEMR vs NVCR Comparison
SEMR vs NVCR Comparison
Compare SEMR & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEMR
- NVCR
- Stock Information
- Founded
- SEMR 2008
- NVCR 2000
- Country
- SEMR United States
- NVCR Switzerland
- Employees
- SEMR N/A
- NVCR N/A
- Industry
- SEMR EDP Services
- NVCR Medical/Dental Instruments
- Sector
- SEMR Technology
- NVCR Health Care
- Exchange
- SEMR Nasdaq
- NVCR Nasdaq
- Market Cap
- SEMR 1.4B
- NVCR 1.9B
- IPO Year
- SEMR 2021
- NVCR 2015
- Fundamental
- Price
- SEMR $8.60
- NVCR $17.60
- Analyst Decision
- SEMR Buy
- NVCR Buy
- Analyst Count
- SEMR 8
- NVCR 7
- Target Price
- SEMR $17.00
- NVCR $32.43
- AVG Volume (30 Days)
- SEMR 793.1K
- NVCR 1.4M
- Earning Date
- SEMR 08-04-2025
- NVCR 07-24-2025
- Dividend Yield
- SEMR N/A
- NVCR N/A
- EPS Growth
- SEMR N/A
- NVCR N/A
- EPS
- SEMR 0.05
- NVCR N/A
- Revenue
- SEMR $396,021,000.00
- NVCR $621,711,000.00
- Revenue This Year
- SEMR $21.84
- NVCR $5.56
- Revenue Next Year
- SEMR $18.46
- NVCR $9.19
- P/E Ratio
- SEMR $180.34
- NVCR N/A
- Revenue Growth
- SEMR 22.75
- NVCR 18.27
- 52 Week Low
- SEMR $7.90
- NVCR $14.17
- 52 Week High
- SEMR $18.74
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- SEMR 34.11
- NVCR 49.74
- Support Level
- SEMR $8.74
- NVCR $16.81
- Resistance Level
- SEMR $9.10
- NVCR $18.59
- Average True Range (ATR)
- SEMR 0.29
- NVCR 0.74
- MACD
- SEMR 0.01
- NVCR 0.08
- Stochastic Oscillator
- SEMR 1.34
- NVCR 56.18
About SEMR SEMrush Holdings Inc.
SEMrush Holdings Inc is engaged in the online visibility management software-as-a-service (SaaS) platform. Its platform utilizes data and intelligence at the core surrounded by AI-powered interconnected hubs focused on search engine optimization, paid advertising, social media management, local marketing, brand marketing, and content marketing Geographically, it generates revenues from the United States, the UK, and Others.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.